United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 21:00:00 18/05/2026 BST			5-day change	1st Jan Change
566.99 ^USD	-0.28%		-0.51%	+16.37%

08:39am	United Therapeutics Insider Sold Shares Worth $5,397,077, According to a Recent SEC Filing	MT
05-18	Markets Run Into Higher Yields

Transcript : United Therapeutics Corporation, Q2 2025 Earnings Call, Jul 30, 2025

Published on 07/30/2025 at 04:36 pm BST - Modified on 07/31/2025 at 02:35 am BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2025 Corporate Update. My name is Steve, and I'll be your conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about United Therapeutics Corporation

08:39am	United Therapeutics Insider Sold Shares Worth $5,397,077, According to a Recent SEC Filing	MT
05-18	Markets Run Into Higher Yields
05-18	United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial	MT
05-17	United Therapeutics announces Advance Outcomes study of ralinepag	RE
05-16	United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial	CI
05-15	United Therapeutics Insider Sold Shares Worth $5,744,746, According to a Recent SEC Filing	MT
05-14	United Therapeutics Insider Sold Shares Worth $5,497,166, According to a Recent SEC Filing	MT
05-13	Varda Space Industries And United Therapeutics Collaborate To Advance Microgravity-Enabled Treatments For Rare Pulmonary Disease	CI
05-13	United Therapeutics, Varda to Study Space-Based Drug Manufacturing for Pulmonary Disease Treatments	MT
05-13	Varda Space Industries and United Therapeutics collaborate to advance microgravity-enabled treatments for rare pulmonary disease	RE
05-11	United Therapeutics Corporation Presents New Data from TETON-1, Advance Outcomes, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis	CI
05-11	United Therapeutics Insider Sold Shares Worth $5,496,084, According to a Recent SEC Filing	MT
05-11	United Therapeutics Insider Sold Shares Worth $5,785,775, According to a Recent SEC Filing	MT
05-07	United Therapeutics Insider Sold Shares Worth $5,600,468, According to a Recent SEC Filing	MT
05-07	United Therapeutics Insider Sold Shares Worth $4,870,054, According to a Recent SEC Filing	MT